<DOC>
	<DOCNO>NCT02231749</DOCNO>
	<brief_summary>The purpose study compare objective response rate , progression free survival overall survival Nivolumab combine Ipilimumab Sunitinib monotherapy patient previously untreated Renal Cell Cancer .</brief_summary>
	<brief_title>Nivolumab Combined With Ipilimumab Versus Sunitinib Previously Untreated Advanced Metastatic Renal Cell Carcinoma ( CheckMate 214 )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Histological confirmation renal cell carcinoma ( RCC ) clearcell component Advanced ( amenable curative surgery radiation therapy ) metastatic ( AJCC Stage IV ) RCC No prior systemic therapy RCC follow exception : 1 . One prior adjuvant neoadjuvant therapy completely resectable RCC therapy include agent target vascular endothelial growth factor ( VEGF ) VEGF receptor recurrence occur least 6 month last dose adjuvant neoadjuvant therapy Karnofsky Performance Status ( KPS ) least 70 % Measurable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 Tumor tissue [ formalinfixed paraffinembedded ( FFPE ) archival recent acquisition ] must receive central vendor ( block unstained slide ) order randomize subject study treatment . ( Note : Fine Needle Aspiration [ FNA ] bone metastases sample acceptable submission ) Any history current central nervous system ( CNS ) metastases . Baseline image brain require within 28 day prior randomization Prior systemic treatment VEGF VEGF receptor target therapy ( include , limited , Sunitinib , Pazopanib , Axitinib , Tivozanib , Bevacizumab ) Prior treatment antiprogrammed death ( PD ) 1 , antiPDL1 , antiPDL2 , antiCD137 , anticytotoxic Tlymphocyte antigen 4 ( CTLA4 ) antibody , antibody drug specifically target Tcell costimulation checkpoint pathways Any active recent history know suspect autoimmune disease recent history syndrome require systemic corticosteroid ( &gt; 10 mg daily Prednisone equivalent ) immunosuppressive medication except syndrome would expect recur absence external trigger . Subjects vitiligo type I diabetes mellitus residual hypothyroidism due autoimmune thyroiditis require hormone replacement permit enroll Any condition require systemic treatment corticosteroid ( &gt; 10 mg daily Prednisone equivalent ) immunosuppressive medication within 14 day prior first dose study drug . Inhaled steroid adrenal replacement steroid dose &gt; 10 mg daily Prednisone equivalent permit absence active autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>